Pembrolizumab
BioXcel Therapeutics,Merck
['prostate', 'crpc', 'pembro', '$mrk']
$btai
#asco23 poster
#ascogu23
first-in-class oral innate immune activator #bxcl701 combined w/ pembrolizumab $mrk in patients w/
metastatic castration-resistant prostate cancer (mcrpc) of small cell neuroendocrine (scnc)
phenotype: phase 2a final results 